6-K filed Aug 13, 2026 at 07:55 ET
Ascendis Pharma reported a transformative Q2 2026 with revenue surging to EUR 339.3M (up 115% YoY) driven by YORVIPATH growth and the YUVIWEL launch, generating a net profit of EUR 207.0M vs a loss of EUR 38.9M a year ago. The company also recognized a EUR 679.6M deferred tax asset and sold a Priority Review Voucher for $187.5M, while fully redeeming its $575M convertible notes via equity conversion, strengthening the balance sheet. The strong commercial execution and pipeline progress (COACH combination therapy data, EU MAA decision for YUVIWEL expected Q4 2026) support a bullish outlook, though elevated SG&A costs from commercial expansion and ongoing IP litigation with BioMarin are risks to monitor.